Multicenter, phase III study comparing imatinib (ST1571, Glivec) standard dose (400 mg/day) with imatinib high dose induction (800 mg/day) followed by standard dose maintenance (400 mg/day) in pretreated CML [chronic myeloid leukaemia] patients in chronic phase

Trial Profile

Multicenter, phase III study comparing imatinib (ST1571, Glivec) standard dose (400 mg/day) with imatinib high dose induction (800 mg/day) followed by standard dose maintenance (400 mg/day) in pretreated CML [chronic myeloid leukaemia] patients in chronic phase

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms ISTAHIT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Feb 2011 Status changed from recruiting to completed.
    • 22 Jun 2010 Results reported at EHA in June 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top